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Objectives: To compare the time required to achieve lysis with the pulse spray technique and the conventional slow 
continuous infusion technique. 
Design: Prospective randomised open Study. 
Methods: Eighteen patients uitable for intra-arterial thrombolytic herapy with conventional and pulse spray technique 
were randomised 1:1 to receive ither pulse spray thrombolysis with 0.33 mg/ml rt-PA injected as a bolus of 0.2 ml or 
conventional thrombolysis with 0.05 mg/ml rt-PA infused at a rate of 10 ml/h. 
Results: The age, duration of symptoms, length of occlusion and prethrombolysis'ankle brachial pressure index were 
comparable in the two groups. The median duration of thrombolytic herapy in the pulse spray group was 195 min (range 
90-1260) compared to1390 rain (range 300 - 2400) in the Conventional group. The difference between the two groups was 
significant, p < 0.002 (Mann-Whitney test). 
Conclusions: Significantly shorter time is required to achieve local thrombolysis with pulse spray compared to the 
conventional infusion method. 
Introduction 
There is a consensus that percutaneous transluminal 
angioplasty (PTA) is the treatment of choice for 
symptomatic stenoses in the iliac, femoral and popli- 
teal segments. 1 In situ thrombosis, however, can 
supervene resulting in acute deterioration in the 
condition of the limb, and is now recognised as the 
commonest cause of acute lower limb ischaemia. 2 
Local thrombolytic therapy offers the opportunity of 
dissolving the thrombus and unmasking the under- 
lying stenosis or stenoses which can then be subjected 
to PTA. A primary failure of thrombolysis or reocclu- 
sion at a later date does not usually preclude sub- 
sequent surgical intervention. Similarly in grafts that 
occlude beyond the first 30 days of the operation, local 
thrombolytic therapy allows clearance of the graft and 
unmasking of the underlying problem which can then 
be dealt with either by a percutaneous catheter- 
directed intervention or limited surgery. 3'4 The main 
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drawback of the conventional intra-arterial infusion 
thrombolytic therapy has been the length of time 
required to restore circulation to the ischaemic leg 
rendering it unsuitable for severe limb threatening 
ischaemia with sensory deficit9 Because of this throm- 
bolytic therapy is not regularly used in many vascular 
surgical units. In a pilot study we have shown that 
rapid thrombolysis can be achieved with the pulse 
spray technique (PST) within 2 h as opposed to 25 h 
with our previous experience with conventional low 
dose infusion technique (CT). 6 In the present study 
pulse spray thrombolysis was compared with the 
conventional infusion method in a prospective rando- 
mised trial. 
Patients and Methods 
The study was conducted with the approval of the 
Hospital Ethics Committee. Informed consent was 
obtained from each patient. The sample size of the 
study was estimated from the findings of the open 
studies with PST with rt-PA and conventional throm- 
bolysis with rt-PA carried out previously in our unit 7 
as follows: 
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m = sample size of group 1 = 120 
n = sample size of group 2 = 38 
SD 1 = standard eviation of group 1 = 17.3 h 
SD 2 = standard eviation of group 2 = 3.3 h 
Standardised estimated ifference (o) = ~/ 
(m - 1) SD12 + (n - 1) SD2 2 
m+n-2  
Standardised estimated ifference (o) = ~/230.88 = 15.1 
Sample size for difference between two means with a 
significance l vel of 0.05, i.e. fi = 1.96 and a power of 
90%, i.e. R = 1.28 can be estimated by the following 
formula: s 
/2 = 2 [ (z2 0~ + Z 2 ~) O 12 
d 
Mean duration of thrombolysis with 
CT (ml) = 31.7 h 
Mean duration of thrombolysis with 
PST (m2) = 3.4 h 
Difference between the two means 
(d) ml - m2 = 28.3 h 
Standardised estimated ifference (o) = 15.1 
n = 2[ (1.28 + 1.96)15.1 ]2 
28.3 
n=6 
Therefore six patients were required in each group to 
have a 90% power to detect rue difference of the 
magnitude observed in the open studies at a 5% level 
of significance. We decided to study 18 patients which 
was 50% more than the estimated sample size. 
Eighteen patients suitable for local thrombolysis 
were randomised 1:1 to receive pulse spray or conven- 
tional thrombolysis. Randomisation was carried out 
after the arteriogram had been performed and the 
occlusion traversed with a guide wire. The exclusion 
criteria for the study were: (i) active internal haemor- 
rhage; (ii) cerebrovascular accident within the preced- 
ing 2 months; (iii) major surgery within 2 weeks; (iv) 
infected bypass grafts; (v) pregnancy; (vi) inability to 
provide consent; (vii) infective endocarditis; (viii) 
inability to traverse the occlusion with a guidewire; 
(ix) inability to withstand further ischaemia up to 
24 h (total ischaemia with rapidly progressing sensory 
and motor deficit); (x) presence of irreversible ischae- 
mic injury. 
The end point for the cessation of thrombolytic 
therapy were: (i) complete radiological lysis; (ii) no 
radiological and clinical improvement on two assess- 
ments over a period of 12 h; (iii) onset of irreversible 
ischaemic injury during the course of therapy; (iv) 
occurrence of major haemorrhagic complication. 
The pulse spray catheters (E-Ze-M Ltd High Road 
London) used in this study were 5 F in size and 
measured 90 or 135 cm in length. The spray generating 
segments spanned 10, 20 or 30 cm at the distal end of 
the catheter. The catheters were selected according to 
the length of the occlusion and portal of catheter entry. 
When the occlusion was greater than 30 cm in length 
the proximal part of the occlusion was treated first. 
Lacing or preliminary treatment ofthe entire occlusion 
was not performed to avoid destabilisation of the 
thrombus and distal embolisation. Recombinant 
human tissue type plasminogen activator (Actilyse®), 
Boehringer Ingleheim, Bracknell Berkshire, U.K.) was 
used in a concentration of 0.33 mg/ml  which was 
prepared by dissolving 20 mg rt-PA in 20 ml of water 
and diluting in another 40 ml of 0.9% NaC1. A 
purpose-built pulse spray injector (Angiodynamics 
Ltd., Glenfalls, New York, U.S.A.) was programmed to
deliver a bolus of 0.2 ml every 15 s for the first 15 min 
and every 30 s thereafter. Following the arteriogram a 
pulse spray catheter of appropriate l ngth was posi- 
tioned and the patient was transferred tothe recovery 
area in the angiography suite for the administration f 
the thrombolytic therapy. Haemodynamic and 
femoral puncture site monitoring was performed by 
observations every 15 min by the Vascular Surgical 
Research Fellow assisted by a nurse. Radiological 
progress of lysis was monitored with angiograms at 
variable intervals ranging from 30-120 min guided by 
the clinical state and depending on access to the 
angiography table. Percutaneous transluminal balloon 
dilatation of any underlying stenosis was performed 
at the same session and if there was any residual 
thrombus at this stage then the catheter was left for 
slow infusion of rt-PA via the end hole at a rate of 1 
mg/h. 
For conventional lysis a 4 or 5 F end hole straight 
catheter was used. With the tip of the catheter 
embedded into the distal end of the occlusion the rt- 
PA was infused at a rate of 0.5 mg/h  with the aid of 
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MS 2000 Syringe Pump (Graseby Medical Ltd., Colo- 
nial Way, Watford, Herts, U.K.). Radiological monitor- 
ing was performed with 'portable arteriogram' at 
intervals of 3-8 h depending upon the clinical condi- 
tion and rate of lysis observed on the preceding 
arteriogram. The arteriogram was performed with a 
mobile X-ray machine (GEC Ltd.) and a large format 
(35 × 43 cm) film. Single radiographs were exposed 
during rapid injection of 10 ml undiluted Niopam 300 
(Merck Ltd.). The position of the end of the catheter 
was withdrawn to maintain intrathrombic infusion 
according to the findings of the arteriogram. When 
lysis was completed, the patient was transferred tothe 
angiography suite for angioplasty of any underlying 
stenosis and to enable a thorough radiological exam- 
ination to exclude any residual problem. 
The age, duration of symptoms, length of occlusion 
and severity of ischaemia in the two groups are shown 
Table 1. Age, duration of symptoms, length of occlusion and 
severity of ischaemia in the two groups 
Pulse spray Conventional Mann- 
group median group median Whitney 
(range) (range) 
Age (years) 71 (63-92) 74 (55-84) p=0.79 
Duration of 
symptoms (days) 21 (1-42) 12 (1-42) p=0.85 
Length of 
ocdusion (cm) 12 (3~0) 8 (5-55) p=0.72 
Severity of ischaemia 
Viable 2 3 X 2. 
Threatened viability 7 6 p<0.9 
in Table 1. The clinical categories outlined by the Ad 
Hoc Committee on Reporting Standards, Society for 
Vascular Surgery / North American Chapter, Inter- 
national Society for Cardiovascular surgery was used 
for describing the severity of ischaemia. 9 The site of 
Table 2. Site of occlusion 
Pulse spray Conventional 
CFA and SFA 1 1 
SFA 2 1 
SFA and POP 1 2 
POP 3 3 
Femorofemoral graft 0 1 
Femoropopliteal graft 1 1 
Femorotibial graft 1 0 
Abbreviations: CFA = common femoral artery; SFA = superficial 
femoral artery; POP = popliteal artery. 
occlusion in the two groups is shown in Table 2. The 
criteria used for defining successful thrombolysis was 
in accordance with the standard previously recom- 
mended by our unit 1° as shown in Table 3. 
Statistical analysis was carried out using non para- 
metric tests, Mann-Whitney U-test for comparing the 
two groups and Wilcoxon matched pair signed rank 
test for changes within the same group. The 9( 2 test was 
used with Yates' correction for the categorical 
variables. 
Results 
The total median duration of therapy was 195 min 
(range 90-1260) with the pulse spray and 1350 min 
(range -2400) with conventional thrombolysis (Fig. 1). 
There was a highly significant difference between the 
duration in the two groups, p < 0.002 (Mann-Whitney 
test). The changes in the ankle brachial index (ABI) 
after thrombolysis and angioplasty where performed 
in both the groups are shown in Figs 2, 3. In the 
conventional group the ABI increased from a pre-lysis 
median value of 0 to 0.5 (p < 0.02, Wi!coxon paired 
test). In the pulse spray group the ABI increased from 
a pre-lysis median value of 0 to a post-lysis value of 
0.9 (p < 0.0001, Wilcoxon paired test). Thrombolysis 
was successful in 8/9 (88.8%) of the patients in the 
pulse spray group and 5/9 (55.5%) in the conventional 
group. One patient in the pulse spray group required 
adjunctive surgical intervention in the form of an 
extension graft due to an abnormality at the distal 
anastomosis, which was unmasked by thrombolysis. 
Therefore, successful c inical outcome was achieved in 
all patients who received pulse spray thrombolysis. 
The difference in the success rate between the two 
groups did not reach statistical significance probably 
because of the small numbers, (p < 0.9, chi-square with 
Yates' correction). Minor groin haematoma were 
encountered in both groups. No major complication 
occurred in the PST group. One patient died and 
another two patients required an above- and a below- 
knee amputation within 30 days in the conventional 
group. 
Discussion 
Despite encouraging reports on the results of intra- 
arterial thrombolysis (IAT) over the last decade, 11-13 a 
survey carried out in 1990 showed that the majority of 
vascular surgeons had never or only sporadically used 
IAT for the management of peripheral ischaemia. 14
The poor response rate of 58% in this survey may also 
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Table 3. Criteria for successful thrombolysis 
Radiological evidence of lysis with arterial recanalisation at least as 
far as the next major collateral 
An increase in the ABI _~ 0.2 
Limb salvage at 30 days without recourse to reconstructive surgery at 
the level at which lysis was performed 
No clinical evidence or rethrombosis within the first 30 days (i.e. 
preservation f the increase in the ABI) 
reflect indifference towards thrombolytic therapy. The 
main reasons stated by the responders for not using 
IAT were doubts regarding its efficacy and lack of 
radiological support. Both these reasons are rooted in 
experience of conventional thrombolysis which is time 
consuming and imposes considerable strain on 
resources. During conventional thrombolysis patients 
require careful clinical monitoring in an intensive care 
or high dependency area. Radiological monitoring 
frequently requires out of hours angiography and 
some radiology departments may not be able to 
provide such a service. The slow action of CT means 
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Fig. 1. Duration of thrombolytic therapy. 
that cases where there is a doubt about the ability of 
the limb to withstand further ischaemia for 24 h or 
more cannot be treated. Even in experienced centres 
the success rate in a well-selected group of patients is 
of the order of 60%. 1° The issue is further confounded 
by the paucity of controlled trials and lack of 
uniformity in the reporting standards used in the 
literature on intra-arterial thrombolytic therapy. ~s 
In our pilot study PST was successful in 75% of the 
cases including those with sensory and motor deficit 
and the median duration of thrombolysis was 137.5 
minutes. This was a highly significant reduction 
compared to our previous experience with conven- 
tional thrombolysis. 6 In the present stud)5 a significant 
difference in the time required to achieve lysis was 
maintained with a median duration of 195 min with 
PST compared to 1350 min with conventional throm- 
bolysis when the two techniques were compared in a 
randomised trial (p < 0.002). 
The term pulsed spray thrombolysis was first 
coined by Bookstein, who reported rapid thrombolysis 
in occluded dialysis grafts, peripheral bypass grafts 
and native arteries with a technique of spraying 
urokinase into the occlusion. 16 In a retrospective 
review of this technique, Valji and Bookstein ~7 
reported complete or near complete lysis in 23/23 
cases of native arterial occlusion and 24/25 cases of 
bypass graft occlusions, with a mean lysis time of 65 
min for native arteries and 93 min for bypass grafts. 
However, clinical success without surgical interven- 
tion was achieved in only 15/23 native arteries and 
14/25 bypass grafts. The duration of lysis was 
documented in only first 15 cases of arterial occlusion 
and first 18 cases of graft occlusion. The retrospective 
nature of this study with incomplete documentation 
detracts from the significance of this important obser- 
vation on a technique of accelerated local 
thrombolysis. 
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Fig. 2. Change in ABI following pulse spray thrombolysis. 
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Fig. 3. Change in ABI following conventional thrombolysis. 
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More recently Kandarpa et al. have reported a 
randomised trial of forced periodic infusion and slow 
continuous infusion method, is Although they used a 
similar catheter system as we have done in the present 
study, their results are very different. The mean 
duration of thrombolysis in the forced periodic infu- 
sion group was 20+14 h and 28+26 h in the 
conventional s ow infusion group. Interestingly, in the 
conventional slow infusion group, they used pulse 
spray (E-Ze-M) catheters initially to deliver 25 000 
units of urokinase very 10 cm of the occlusion prior 
to commencement of slow infusion. The explanation 
offered for inability to achieve rapid lysis with the 
pulse spray catheter is that once the flow is restored 
through the occluded segment, the clot penetrating 
ability of the spray is lost due to change in the 
direction of spray due brisk antegrade blood flow. 
However, this is merely a conjecture and certainly did 
not occur in our experience. The major difference was 
in the choice of agent and regime, which could largely 
account for our different results. 
While the rate of administration with the pulse 
spray regime was nearly 20 times greater than the 
conventional infusion group, it seems unlikely that the 
highly significant difference in lysis time observed is 
mainly due to more rapid administration of rt-PA. In 
other studies where high dose rt-PA has been used at 
a much faster rate in the form of boluses the rate of 
lysis is much slower than observed in our study. One 
of the earlier eports on bolus administration of 15 m R 
of rt-PA over 30 min showed accelerated lysis. 
However, the majority of patients in this study had 
bypass graft occlusion (60%) and in such cases, it is the 
practice of the authors of this particular study to 
employ clot aspiration following rt-PA administration. 
The rapid clearance of thrombus therefore cannot be 
attributed to high dose of rt-PA alone. Moreover, in a 
subsequent s udy by Ward et at. 2° a mean lysis time of 
14.4 hours and a success rate of 48% was achieved 
following administration of 21 mg rt-PA during the 
first hour. Similar results have been reported by 
Braithwaite et al. 21 who administered 18.5 mg rt-PA 
over the first hour and achieved a mean lysis time of 
11 h. These studies clearly support he hypothesis that 
it is the technique of intrathrombic injection of rt-PA 
and not merely the rate of administration which is 
responsible for rapid thrombolysis with the pulse 
spray technique. 
Multi-level infusion catheters are available for infu- 
sion thrombolysis, and their use can eliminate the 
need for repositioning the catheter in short occlusions. 
However, their use has not been reported to reduce 
the duration of thrombolysis 22"23 and most centres in 
the U.K. still use an end-hole catheter for conventional 
infusion thrombolysis. We, therefore, used an end-hole 
catheter for conventional thrombolysis in the present 
study. 
The success rate in the present study with pulse 
spray lysis is 8/9 (88.8%) compared to 5/9 (55.5%) 
with the conventional lysis, but due to the small 
numbers in each group this difference is not statisti- 
cally significant. It is desirable and important to 
evaluate the difference in outcome in terms of success 
rate between pulse spray and conventional lysis in a 
prospective randomised trial but the large sample size 
required in each group for such a study is beyond the 
scope of any single centre. If we estimate the sample 
size for such a study using data from our previous 
experience with pulse spray and conventional lysis 7 
then 426 will be required in each group to have the 
statistical power to detect a true difference in the 
success rate. At the current rate of recruitment it 
would take more than 15 years to complete such a 
study or nearly eight years if the power of the study is 
reduced and a greater difference in success rate is 
expected. Large-scale multicentre trials like the 
STILE 24 (Surgery versus thrombolysis in limb ischae- 
mia) can address broad issues and provide valuable 
data but it would be difficult to organise such a study 
for specific techniques of thrombolysis. 
The rapid rate of lysis with pulse spray means that 
where resources are available to institute pulse spray 
thrombolysis without dela)~ patients with rapidly 
progressing sensory and motor deficit who could not 
withstand a prolonged trial of conventional thrombol- 
ysis can be safely treated with thrombolytic therapy. 
Apart from clear cases of embolic occlusion with 
normal pulses in the contralateral limb, where balloon 
embolectomy with an on-table completion arterio- 
gram may be considered acceptable, a preliminary 
arteriogram is usually obtained in patients with acute 
limb ischaemia prior to surgical intervention. Under 
these circumstances a catheter can be positioned with 
minimum delay for local thrombolytic therapy. Due to 
the rapid rate of lysis with pulse spray, it is easy to 
assess the response to therapy. If there is minimal or 
no radiological improvement after 1 h of pulse spray 
thrombolysis then alternative surgical intervention 
can be carried out without loss of valuable time even 
in the most urgent cases. The short duration of therapy 
eliminates the need for prolonged intensive monitor- 
ing and limits the out of hours demand on the 
radiology department. With close co-operation 
between the vascular surgeons and radiologists, PST 
can be effectively used for treating most cases of acute 
limb ischaemia, irrespective of the severity of 
ischaemia. 
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